MARKET

ACOR

ACOR

Acorda
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7100
-0.0010
-0.14%
After Hours: 0.7100 0 0.00% 18:24 07/08 EDT
OPEN
0.7200
PREV CLOSE
0.7110
HIGH
0.7287
LOW
0.7050
VOLUME
778.36K
TURNOVER
--
52 WEEK HIGH
7.35
52 WEEK LOW
0.7000
MARKET CAP
34.07M
P/E (TTM)
-0.1455
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ACOR stock price target is 3.800 with a high estimate of 10.00 and a low estimate of 1.000.

EPS

ACOR News

More
Do Hedge Funds Love Acorda Therapeutics Inc (ACOR)?
Insider Monkey · 8h ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Acorda Therapeutics, Inc. - ACOR
Newsfile · 06/16 21:46
Teladoc (TDOC) Soars 193% in a Year: What's Behind the Rally?
Zacks · 06/12 14:36
Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock?
Zacks · 06/09 15:01
Acorda (ACOR) Down 11.8% Since Last Earnings Report: Can It Rebound?
Zacks · 06/04 16:31
Acadia Healthcare Ties Up for Improved Behavioral Services
Zacks · 06/03 14:05
Acorda Therapeutics, Inc. 2020 Q1 - Results - Earnings Call Presentation
Seeking Alpha - Article · 05/08 11:29
DexCom +4.3% on move to S&P 500; Domino's moves up
DexCom (NASDAQ:DXCM) is up 4.3% postmarket as it's making a move to the S&P 500, to replace Allergan (NYSE:AGN) - set to be acquired by AbbVie. And Salesfo
seekingalpha · 05/07 02:29

Industry

Biotechnology & Medical Research
+1.13%
Pharmaceuticals & Medical Research
+0.50%

Hot Stocks

Symbol
Price
%Change

About ACOR

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
More

Webull offers kinds of Acorda Therapeutics Inc stock information, including NASDAQ:ACOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACOR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACOR stock methods without spending real money on the virtual paper trading platform.